+39 02 610346.1 - info@newron.com

Press Releases

Filter by year
  • july102019

    Newron’s commercialization partner Zambon and Valeo Pharma announce the launch of Onstryv® (safinamide) for Parkinson’s disease in Canada

     

  • june282019

    Newron Receives First Tranche from Financing Agreement with European Investment Bank (EIB)

     

  • june272019

    Newron Pharmaceuticals now also listed on the primary market of the Düsseldorf Stock Exchange and on XETRA

     

  • june132019

    Newron Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

  • may282019

    Newron Pharmaceuticals provides update on regulatory status of evenamide for the treatment of schizophrenia

     

  • may232019

    Newron Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

  • april22019

    Shareholders accepted all motions at the 2019 AGM

     

  • march52019

    Newron announces 2018 financial results and provides outlook for 2019

     

  • february282019

    Newron Supports Global Rare Disease Day® 2019

     

  • february202019

    Newron to Present at the 8th Annual SVB Leerink Global Healthcare Conference

  • february12019

    Newron Completes Patient Enrollment in Pivotal STARS Study

     

  • january312019

    Newron Pharmaceuticals to Present at the 21st Annual BIO CEO & Investor Conference in New York

  • january162019

    Zambon together with Valeo Pharma announce the approval of Onstryv® (safinamide) for PD in Canada